Although anaemia has a significant negative impact on morbidity and mortality in renal dysfunction, it remained a particularly difficult challenge in this environment due to the very high cost of erythropoietin (EPO), which has necessitated higher blood transfusion rates with attendant consequences. This evidence concerns the gene EPO and Abnormal renal physiology.